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The dual methyltransferase METTL13 targets
N terminus and Lys55 of eEF1A and modulates
codon-speciﬁc translation rates
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Eukaryotic elongation factor 1 alpha (eEF1A) delivers aminoacyl-tRNA to the ribosome and
thereby plays a key role in protein synthesis. Human eEF1A is subject to extensive
post-translational methylation, but several of the responsible enzymes remain unknown.
Using a wide range of experimental approaches, we here show that human methyltransferase
(MTase)-like protein 13 (METTL13) contains two distinct MTase domains targeting the N
terminus and Lys55 of eEF1A, respectively. Our biochemical and structural analyses provide
detailed mechanistic insights into recognition of the eEF1A N terminus by METTL13. More-
over, through ribosome proﬁling, we demonstrate that loss of METTL13 function alters
translation dynamics and results in changed translation rates of speciﬁc codons. In summary,
we here unravel the function of a human MTase, showing that it methylates eEF1A and
modulates mRNA translation in a codon-speciﬁc manner.
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Methylation is a common post-translational modiﬁcation(PTM) of proteins, and is mostly introduced by site-speciﬁc S-adenosylmethionine (AdoMet)-dependent
methyltransferase (MTase) enzymes. The most studied type of
protein methylation is the methylation of lysine and arginine, but
residues such as glutamine and histidine as well as the N and C
termini of proteins can also be subjected to methylation1. The
human genome has been predicted to encode ~200 MTases,
which have been categorized and grouped based on distinct
structural features2. The so-called seven-β-strand (7BS) MTases
represent the largest group and encompass roughly 130 human
enzymes. The second largest group comprises the SET (Su(var)
3–9, Enhancer-of-zeste, Trithorax) domain-containing enzymes,
which account for about 50 human proteins. Enzymes of the 7BS
class have been reported to act on a wide range of substrates
including metabolites, nucleic acids, and proteins, whereas SET
domain MTases appear to exclusively target lysine residues in
proteins1,3.
The ε-amino group of a lysine side chain can accept up to three
methyl groups. The functional roles of lysine methylation have
been intensively studied in the context of chromatin biology,
where distinct methylation states of lysines in histone proteins
contribute to deﬁning chromatin packing and transcriptional
activity4,5. In recent years, lysine methylation of non-histone
proteins has emerged as a growing ﬁeld of research and several
lysine (K)-speciﬁc methyltransferases (KMTs) have been
identiﬁed6.
The N terminus of eukaryotic proteins is often modiﬁed and
most frequently subjected to enzymatic acetylation. Acetylation
can occur on the α-amino group of the initiator methionine
(iMet) but also on the second amino acid after removal of iMet by
methionine aminopeptidases7. Alternatively, the N terminus can
be subject to methylation and this PTM is biochemically similar
to ε-amino methylation of lysine side chains in the sense that the
α-amino group can accept up to three methyl groups. Despite
being ﬁrst described more than three decades ago, N-terminal
methylation represents a poorly characterized PTM and, to date,
only two human N-terminal methyltransferases—NTMT1 and
NTMT2—have been identiﬁed8,9. Notably, both the NTMT
enzymes recognize and target a X-Pro-Lys consensus sequence
and several substrates including the regulator of chromosome
condensation (RCC1) and the histone H3-like centromeric pro-
tein A (CENP-A) have been identiﬁed. Both for RCC1 and
CENP-A, the lack of N-terminal methylation was shown to cause
defects related to the formation and function of the mitotic
spindle10,11.
Translation of mRNA to protein is mediated by ribosomes and
is a three-stage process involving initiation, elongation, and ter-
mination12. During elongation, eEF1A performs the essential
function of delivering aminoacyl-tRNA to the ribosome, in a
process where the ribosome samples the available pool of ternary
aminoacyl-tRNA–eEF1A-GTP complexes. Upon productive base
pairing between the anti-codon of the tRNA and the exposed
mRNA codon in the ribosome acceptor site (A-site), eEF1A
hydrolyzes GTP, and the resulting eEF1A–GDP complex is
released allowing elongation of the associated nascent peptide
through the formation of a peptide bond. In humans, two highly
similar eEF1A paralogs exist, denoted eEF1A1 and eEF1A2 (here
collectively referred to as eEF1A). It is well established that
mammalian eEF1A is extensively methylated on distinct lysine
residues including Lys36, Lys55, Lys79, Lys165, and Lys318, as
well as on the N terminus13,14. Human KMTs targeting Lys3615,
Lys7914, Lys16516,17, and Lys31818 have recently been identiﬁed,
but the enzyme(s) targeting Lys55 and the N terminus have so far
remained elusive.
Through a combination of quantitative mass spectrometry
(MS)-based proteomics screens, gene-targeted cells, and in vitro
enzymology, we here reveal METTL13 as the enzyme responsible
for methylation of eEF1A at the N terminus and Lys55. More-
over, we show that loss of METTL13 activity in cells has func-
tional consequences and results in altered translation rate of
speciﬁc codons.
Results
Identiﬁcation of METTL13 as an eEF1A methyltransferase.
During our recent efforts to characterize methylation events on
eEF1A, we noticed that its N terminus is trimethylated in cultured
human cells, and this was recently observed and published by
others14. Intrigued by this observation, we sought to identify the
responsible enzyme. Reasoning that the MTase would likely bind
more avidly to its substrate than its product, we performed an
MS-based quantitative interaction peptide pull-down screen19
using a synthetic biotinylated peptide corresponding to N-
terminally unmodiﬁed eEF1A sequence as bait, and the corre-
sponding N-terminally trimethylated peptide as reference, to
enrich interacting proteins from a human cell extract (Fig. 1a).
Proteins binding to the immobilized peptides were digested with
trypsin, and the resulting peptides were analyzed by state-of-the-
art nanoﬂow liquid chromatography tandem mass spectrometry
(LC-MS/MS), followed by protein quantiﬁcation using the
MaxLFQ algorithm20 embedded in MaxQuant software suite21.
In total, 157 proteins were found to be signiﬁcantly enriched by
the unmethylated bait and 174 proteins by its methylated coun-
terpart (Fig. 1b, Supplementary Fig. 1, and Supplementary
Data 1). Importantly, peptide pull-downs intrinsically enrich
proteins that biophysically interact with the bait peptide in vitro
and, consequently, not all hits in such screens are necessarily
biologically relevant.
Interestingly, the putative methyltransferase METTL13 was
among the proteins most strongly enriched by the unmodiﬁed
bait peptide and was consequently chosen for further character-
ization (Fig. 1b). METTL13 harbors two distinct predicted MTase
domains that both belong to the 7BS superfamily (Fig. 1c and
Supplementary Fig. 2). The N-terminal domain (here denoted
MT13-N) belongs to a recently discovered enzyme family
consisting of likely KMTs15 and the C-terminal domain (here
denoted MT13-C) lacks close paralogs, but is distantly related to
spermidine synthase (SpdS) (Fig. 1c). We expressed and puriﬁed
human MT13-N and MT13-C individually as recombinant
proteins from E. coli and assessed their ability to methylate
recombinant eEF1A in vitro. As the conformation of eEF1A is
dependent on nucleotide binding22 and we have previously
observed that the efﬁciency of other eEF1A-speciﬁc MTs can be
modulated by the addition of guanosine nucleotides16,23, the
experiments were performed in the presence of GDP, GTP, or
without exogenously added cofactors. Moreover, we evaluated
eEF1A1 with an afﬁnity tag located at either the N or C terminus
as substrate. Importantly, N-terminal methylation of human
eEF1A occurs on Gly2 after enzymatic removal of the iMet, and
the endogenous methionine aminopeptidase in E. coli is predicted
to process heterologously expressed human eEF1A accordingly24.
These experiments revealed that both MTase domains of
METTL13 were capable of methylating eEF1A in vitro and that
their activities were clearly distinct. MT13-N methylates eEF1A1
irrespective of afﬁnity tag placement at the N or C terminus, and
methylation was inhibited by the addition of nucleotides (Fig. 1d).
In contrast, MT13-C was exclusively able to methylate eEF1A
with a free N terminus (i.e., as C-terminally tagged protein) and
was insensitive to the addition of GDP or GTP (Fig. 1e).
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In conclusion, the above experiments demonstrate that
METTL13 is capable of methylating eEF1A in vitro and suggest
that MT13-C targets the N terminus of eEF1A while MT13-N
methylates a different site.
MT13-C targets the eEF1A N terminus. To evaluate MT13-C for
N-terminal MTase activity on eEF1A, we incubated the recom-
binant enzyme with recombinant eEF1A1 in vitro and quantiﬁed
the N-terminal methylation status of eEF1A by MS. In this
analysis, an N-terminally trimethylated chymotryptic peptide
corresponding to amino acids Gly2-Tyr29 in eEF1A was detected
in the enzyme-treated sample, but not in a control reaction
without MT13-C (Fig. 2a and Supplementary Fig. 3).
Amino groups of proteins can potentially receive up to three
methyl groups through enzymatic methylation, and MTases
introducing a single methyl group per substrate binding event are
referred to as distributive, whereas enzymes introducing multiple
modiﬁcations are denoted as processive. Distributive trimethyla-
tion is characterized by the mono- and dimethylated products
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Fig. 1 Identiﬁcation of METTL13 as an eEF1A-speciﬁc methyltransferase. a Workﬂow of mass spectrometry-based quantitative peptide pull-down screen.
Synthetic peptides corresponding N-terminally trimethylated (Nt-Me3) and unmethylated (Nt-Me0) eEF1A were used as baits to enrich proteins from
HAP-1 cell extracts. b Volcano plot demonstrating enrichment of proteins by the unmodiﬁed (cyan circles) versus N-terminally trimethylated (magenta
circles) bait peptides. The curved line represents the signiﬁcance cutoff (FDR= 0.01 and s0= 0.1). The putative methyltransferase METTL13 is indicated
and all represented proteins are listed in Supplementary Data 1. c Domain organization of METTL13. The boundaries for used constructs encompassing the
N-terminal (MT13-N) and the C-terminal (MT13-C) methyltransferase domains are indicated. d, e Evaluation of METTL13 constructs for eEF1A-speciﬁc
methyltransferase activity. MT13-N (d) and MT13-C (e) were incubated with [3H]-AdoMet and eEF1A1 carrying an N-terminal or C-terminal His-tag in the
absence of cofactors and in the presence of either GDP or GTP. Methylation was visualized by ﬂuorography (top panels) and the membranes were stained
with Ponceau S (bottom panels) to assess protein loading
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being most abundant at low enzyme-to-substrate ratio25. To
assess the processivity of MT13-C, eEF1A1 was incubated with
varying amounts of the enzyme, and the methylation status of the
N terminus was assessed by MS. The N terminus was methylated
in a dose-dependent manner, and the bulk of substrate (~75 %)
was trimethylated at equimolar amounts of enzyme and substrate
(Fig. 2b). Notably, only trace amounts of the mono- and
dimethylated species were detected at limiting amounts of the
enzyme, indicating that MT13-C is a processive enzyme.
To assess whether METTL13 also catalyzes eEF1A methylation
in vivo, the gene was disrupted in HAP-1 cells using CRISPR/
Cas9 technology. To assure knockout (KO) of the gene function,
the guide RNA was designed to target an early exon, upstream of
predicted catalytically important regions (Supplementary Fig. 4a).
A clone harboring a 20 nucleotide deletion in this exon was
chosen for further studies, and the absence of METTL13 protein
was veriﬁed by immunoblotting (Supplementary Fig. 4b). MS
analysis of the N-terminal methylation status of eEF1A in cells
revealed the site to be predominantly trimethylated in wild-type
(WT) cells and exclusively unmodiﬁed in KO cells (Fig. 2c and
Supplementary Fig. 5). Moreover, complementation of the KO
cells with a METTL13 construct partially restored N-terminal
methylation of eEF1A (Fig. 2c).
In summary, these results demonstrate that METTL13 is
required and sufﬁcient for N-terminal methylation of eEF1A in
cells and attribute the activity to the C-terminal MTase domain of
the enzyme.
MT13-C is a highly speciﬁc methyltransferase. Whereas some
protein MTases recognize the three-dimensional structure of their
substrates, others primarily interact with the linear sequence
represented by the targeted amino acid and the surrounding
residues, and such MTases are usually active on the corre-
sponding peptides in vitro26,27. Interestingly, we found that
MT13-C was active on short peptides corresponding to the (iMet-
less) N terminus of eEF1A (Supplementary Fig. 6a). We therefore
set out to investigate the sequence requirements and preferences
for MT13-C-mediated methylation using synthetic peptide arrays.
In these experiments, peptides derived from the ﬁrst 15 amino
acids (after iMet cleavage) of eEF1A were synthesized, where each
peptide harbored a substitution of one of the N-proximal residues
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with each proteogenic amino acid (cysteine and tryptophan
excluded). The array was incubated with MT13-C and [3H]-
AdoMet, and methylation was visualized by autoradiography
(Fig. 3a).
At the ﬁrst sequence position, MT13-C showed a strong
preference for glycine, the residue naturally found at the
N terminus of eEF1A, but some activity was also observed with
N-terminal alanine or proline (Fig. 3a). eEF1A has lysine at
position 2 (P2), and accordingly, MT13-C primarily showed
activity toward peptides with positively charged (lysine and
arginine) or aromatic (phenylalanine and tyrosine) residues at P2,
but some other amino acids, such as glutamine and histidine,
were also tolerated (Fig. 3a). Glutamate is found at position 3 (P3)
in eEF1A, and correspondingly, MT13-C showed a very strong
preference for glutamate at P3 (Fig. 3a). Downstream positions
were generally found to be less important, but the replacement of
the lysine in position 4 typically yielded reduced activity, and no
activity was observed with proline in position 5 (Fig. 3a, b). Based
on the speciﬁcity proﬁle obtained from the peptide array
experiments, we searched the human proteome for proteins that
adhered to the following N-terminal consensus sequence: M-
[GAP]-[KRFYQH]-E-[KRQHIL] (amino acid in eEF1A is
indicated). Through these restricted BLAST searches, we
identiﬁed 49 candidate substrate proteins (Supplementary Data 2)
and generated an array containing 15-mer N-terminal peptides
(without iMet) derived from these proteins to investigate the
activity of MT13-C toward these peptides. Notably, none of the
peptides derived from the candidate substrates were appreciably
methylated (Fig. 3c) and labeling was in all cases below 5%
compared to eEF1A. Based on our experience, such weak labeling
very rarely reﬂects speciﬁc activity of the MTase on the given
peptide substrate, indicating that MT13-C is a highly speciﬁc
enzyme.
To further investigate the speciﬁcity of MT13-C, protein
extracts from HAP-1 WT and METTL13 KO cells were incubated
with the recombinant enzyme and [3H]-AdoMet. Proteins were
then separated by SDS-PAGE, transferred to a membrane and
methylation was visualized by ﬂuorography (Fig. 3d and
Supplementary Fig. 6b). In this experiment, a protein with a
molecular weight matching eEF1A (~50 kDa) was efﬁciently and
exclusively methylated in the extract from KO cells. The absence
of methylation in the WT extract likely reﬂects that iMet-
processed eEF1A is fully trimethylated in the METTL13-
proﬁcient WT cells (Fig. 2c). Importantly, no MT13-C-
mediated methylation of other proteins was detected. Taken
together with the results from the peptide arrays, this ﬁrmly
demonstrates that MT13-C is a highly speciﬁc MTase targeting
the N terminus of eEF1A.
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MT13-C is a novel type of N-terminal MTase. MT13-C repre-
sents a new type of N-terminal MTase. To obtain further insights
into its molecular mechanism, we determined the crystal struc-
ture of its core MTase domain (residues 470–699) (Fig. 4a,
Supplementary Fig. 7 and Supplementary Table 1) in complex
with S-adenosylhomocysteine (AdoHcy), which is a byproduct of
the methylation reaction, representing the demethylated form of
AdoMet. Based on its sequence, MT13-C belongs to the family of
Rossmann fold-like 7BS MTases, and, correspondingly, the
determined structure of the MT13-C MTase domain reveals a
classic 7BS structure, consisting of a twisted 7BS sheet surrounded
by six α-helices, three on each side (Fig. 4a). The closest human
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sequence homolog of MT13-C is SpdS and, accordingly, its 3D
structure matches human SpdS (PDB code: 2o06)28 most closely
(root mean square deviation below 2.2 Å) among the available
entries in the protein data bank. Notably, SpdS is not a MTase,
but rather catalyzes a reaction where spermidine and 5′-methyl-
thioadenosine (MTA) are generated through aminopropyl
transfer from decarboxylated AdoMet to putrescine.
The 7BS enzymes contain certain hallmark sequence motifs,
corresponding to key residues involved in coordination of
AdoMet/AdoHcy. The two most conserved/essential motifs are
denoted motif I and Post I, and include the residues comprising
β-strands 1 and 2, respectively, as well as parts of loop structures
located downstream of these strands29. Although the homocysteyl
moiety of AdoHcy was not fully resolved by electron density, the
MT13-C structure indeed revealed that residues in these motifs
(Gly503 and Glu524 in METTL13) are involved in AdoHcy
coordination, and show a similar positioning as in SpdS (in
complex with MTA) (Fig. 4b). Moreover, MT13-C and SpdS
share a short DG-motif (Asp551-Gly552 in METTL13) localized
after β-strand 3 and not generally found in other 7BS enzymes.
The localization and orientation of the acidic aspartate residue in
this motif allows hydrogen bonding to the primary amine of the
adenosine moiety of AdoHcy and MTA, respectively (Fig. 4b).
The region located downstream of β-strand 4 in the 7BS
enzymes, referred to as motif Post II, encompasses residues
involved in substrate recognition3,6,15. For SpdS, two aspartate
residues (Asp173 and Asp176) in Post II have been shown to be
important for both tetramethylenediamine (putrescine) substrate
binding and efﬁcient catalysis28, and interestingly, MT13-C has
an aspartate residue (Asp575) at the position corresponding to
Asp173 (Fig. 4c). Also, the other residues of motif Post II show a
similar positioning between the two enzymes and MT13-C, in
particular, also has an aspartate residue (Asp577) in spatial
proximity to Asp176 in SpdS (Fig. 4c).
To explore how MT13-C interacts with its peptide substrate,
we modeled the 6-mer peptide (GKEKTH) corresponding to the
N terminus of eEF1A onto the MT13-C structure by molecular
docking. The highest-ranking docking model placed the substrate
peptide in an evolutionary conserved groove with its N terminus
oriented toward AdoHcy (Fig. 4d), i.e., an orientation very similar
to that of putrescine in SpdS. Furthermore, the above-mentioned
Asp577, as well as another highly conserved residue (Asn647),
appear to be involved in peptide substrate coordination (Fig. 4e).
To validate the structural model, we individually mutated to
alanine the side-chain-containing residues implied in AdoMet
binding (Glu524 and Asp551) or substrate peptide coordination
(Asp577 and Asn647), as well as other residues in the so-called
motif Post II (Asp575, Val576, and Ser578), which is important
for substrate recognition and/or catalysis for other 7BS
MTases6,15 and compared the activity of the corresponding
enzymes. We found that Glu524 and Asp575 are required for
enzymatic activity, whereas mutation of all other examined
residues, except Ser578, reduced the activity of MT13-C (Fig. 4f).
Taken together, our combined structural and biochemical
analyses of MT13-C reveal important molecular details about
its interaction with its two substrates (peptide and AdoMet/
AdoHcy) as well as its requirements for enzymatic activity.
Characterization of the MT13-N. MT13-N was recently reported
to belong to a family of likely KMTs15. To identify candidate
substrates for MT13-N, we devised an MS-based proteomics
screen aimed at generating comprehensive coverage of tryptic
peptides30, and consequently lysine methylation sites, in HAP-1
WT and METTL13 KO cells. To achieve this, we combined stable
isotope labeling with amino acids in cell culture (SILAC)31 of WT
and KO cells and ofﬂine fractionation of tryptic peptides by
reversed-phase chromatography at alkaline pH prior to online
nanoﬂow LC-MS/MS analysis (Supplementary Fig. 8a). Across
three biological replicates, we identiﬁed and quantiﬁed roughly
10,000 human proteins with a median sequence coverage above
35% (Supplementary Data 3). Reassuringly, METTL13 was found
to be one of the most underrepresented proteins in the METTL13
KO cells, thereby conﬁrming their genotype (Supplementary
Fig. 8b).
Interrogation of this data set for methylation revealed support
for 132 lysine methylation events comprising 39 mono-methyl, 80
di-methyl, and 13 tri-methyl sites (Supplementary Data 4).
Reassuringly, several previously well-established sites including
Lys116 in Calmodulin32, Lys585 in HSPA533, and Lys525 in
eEF234 were identiﬁed. Notably, MS signal intensities correspond-
ing to dimethylation of Lys55 in eEF1A and monomethylation of
Lys1163 in APOB were signiﬁcantly lower in the METTL13 KO
cells (Fig. 5a). The relative intensity with which a site is detected
is dependent on both the fractional occupancy of the modiﬁcation
and on the relative abundance of the modiﬁed protein. Notably,
APOB protein was strongly underrepresented in the METTL13
KO cells but this was not the case for eEF1A (Supplementary
Fig. 8b), suggesting that only the methylation of the latter is
dependent on METTL13.
To corroborate that METTL13 is responsible for the generation
of Lys55 methylation in vivo, and to estimate the occupancy of
the modiﬁcation, we quantiﬁed the levels of the different
methylated species of an endoproteinase Glu-C-generated eEF1A
peptide encompassing Lys55 in WT and METTL13 KO cells
(Fig. 5b and Supplementary Fig. 9). In WT cells, the dimethylated
species of Lys55 were the predominant form, and the site was
exclusively found unmethylated in the METTL13 KO cells.
Furthermore, complementation of the KO cells with ectopically
expressed METTL13 partially restored methylation. To establish
that MT13-N directly methylates Lys55 in eEF1A, and thus rule
out the possibility that methylation of this site occurs as a
secondary consequence of another METTL13-dependent event
in vivo, we performed in vitro enzyme assays. Recombinant
eEF1A was incubated with MT13-N in the presence of AdoMet,
and the methylation status of Lys55 assessed by MS. This analysis
revealed MT13-N-dependent formation of both mono- and
dimethylation at Lys55 (Supplementary Fig. 10). We then
evaluated a Lys55Arg mutant of eEF1A as a substrate for
MT13-N. In line with previous results, MT13-N efﬁciently
methylated the WT substrate, but eEF1A1 harboring the
Lys55Arg point mutation was not a substrate for methylation
(Fig. 5c), indicating that Lys55 represents the only target site for
MT13-N in eEF1A. In conclusion, the above ﬁrmly demonstrates
that MT13-N is required and sufﬁcient for methylation of Lys55
in eEF1A.
METTL13-mediated methylation in cells and tissues. The N-
terminal domains of eEF1A1 and eEF1A2 are highly homologous,
and consequently proteolytic peptides covering the N termini or
Lys55 are identical. Therefore, to assess whether both paralogs are
subjected to METTL13-mediated methylation in cells, we indi-
vidually overexpressed FLAG-tagged versions of eEF1A1 and
eEF1A2 in HEK-293 cells and subsequently afﬁnity puriﬁed the
proteins and analyzed their methylation status (Fig. 6a, b). In line
with our previous observations in HAP-1 cells (Fig. 2c and
Supplementary Table 2), we found that the dimethylated species
of Lys55 and the trimethylated form of the N terminus were
predominant for both eEF1A paralogs (Fig. 6a, b). Moreover, we
analyzed the methylation status of the METTL13 target sites in a
panel of rat organs including liver, kidney, and intestine (Fig. 6c,
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d). In line with the observations from human cell lines, Lys55 and
the N terminus of eEF1A were mostly di- and trimethylated,
respectively. To further explore whether METTL13-mediated
methylations are regulated under speciﬁc conditions, we assessed
methylation of eEF1A in HeLa cells stressed by 4-nitroquinoline
1-oxide (4NQO) to induce a UV-like response, adenosine dia-
ldehyde (AdOx) to perturb AdoMet metabolism as well as
cycloheximide and anisomycin to perturb mRNA translation. We
found dimethylation of Lys55 and trimethylation of the N ter-
minus to be the dominant species in all analyzed conditions
(Fig. 6e, f), but methylation at both sites was reduced by AdOx
(Fig. 6g, h). AdOx inhibits the AdoHcy hydrolase and
consequently leads to increased levels of AdoHcy in the cell35. As
AdoHcy can act as a competitive inhibitor for AdoMet-dependent
MTases36, it is likely that METTL13 activity is reduced through
competitive inhibition due to an increased AdoHcy-to-AdoMet
ratio in the AdOx-treated cells.
In summary, the above demonstrates that METTL13-mediated
methylation occurs on both paralogs of eEF1A, and in a wide
range of mammalian cells and tissues. Dimethylation of Lys55
and trimethylation of the N terminus was found predominant in
all evaluated conditions and methylation of both sites was
decreased upon AdOx treatment.
Effect of METTL13 knockout on translation. Since METTL13
targets eEF1A, we sought to explore the potential impact of
METTL13 gene deletion on translation dynamics. The decoding
speed of speciﬁc mRNA codons can be estimated by analyzing
their frequency in the ribosomal A-site. This makes it possible to
infer the relative translation rate of individual codons between
two conditions. In accordance with this strategy, we performed
ribosome proﬁling of HAP-1 WT and METTL13 KO cells to
determine the relative A-site occupancy of all codons in the cells
under steady-state conditions (Fig. 7a).
We found that the occupancy of several codons was altered in
the KO cells, relative to the WT cells. Interestingly, codons
encoding the same amino acid generally displayed a similar
behavior (Fig. 7b). In particular, codons for lysine (AAA and
AAG) and histidine (CAC and CAT) showed a higher A-site
occupancy in the KO cells, indicating that they are translated
more slowly in the mutant (Fig. 7b). Conversely, all four codons
for alanine (GCA, GCG, GCC, and GCT) and the single codon
for tryptophan (TGG) displayed a lower occupancy, indicating
faster translation of these codons (Fig. 7b). Furthermore, selected
codons for threonine (ACG), arginine (AGG), and proline (CCG)
were more highly occupied in the KO cells, while asparagine
(AAC), tyrosine (TAC), and serine (TCA and TCC) frequencies
in the A-site were decreased (Fig. 7b). Importantly, occupancy
values of the ﬁrst codon that has not been read by the ribosome
(here denoted A+ 1 site), did not display a similar trend,
emphasizing that these observations are genuine biological events
and not experimental noise. Phenotypes linked to perturbations
of key cellular functions are often complex and a consequence of
both direct and downstream effects. For example, the observed
changes in translation rates of speciﬁc codons could conceivably
be linked to changes in abundance of the relevant aminoacyl-
tRNA synthetases (ARSes) in the KO cells. Reassuringly, the
protein levels of AARS, EPRS, HARS, KARS, NARS, RARS,
SARS, TARS, WARS, and YARS were not altered in the KO cells
(Fig. 7c) and, moreover, the levels of proteins in the eEF1
complex were also unaffected (Fig. 7d).
To potentially obtain further insight into the molecular
function of METTL13-mediated methylation, we performed a
series of additional analyses. First, we analyzed structures of
eEF1A in complex with the guanine nucleotide exchange factor
eEF1Ba37 and the ribosome38 (Supplementary Fig. 11), but the
available structural data suggest no involvement of Lys55 or the N
terminus of eEF1A in inter-molecular interactions. Second, we
analyzed the codon usage and amino acid composition of
proteins categorized as over- or underrepresented in the
proteome of METTL13 KO cells (Supplementary Figs. 12–13).
In summary, the frequency proﬁles for both mRNA codons and
amino acids were found to be indistinguishable across the
populations of modulated, and non-modulated, proteins, suggest-
ing that the altered translation rate of speciﬁc codons in
METTL13 KO cells is not alone a strong determinant of
proteome composition. Third, we explored the potential role of
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eEF1A lysine methylation in modulating its interactome. To this
end, we overexpressed afﬁnity-tagged WT eEF1A and corre-
sponding methylation-deﬁcient mutant, carrying lysine-to-
arginine mutations of the well-established methylation sites
(Lys36, Lys55, Lys79, Lys165, and Lys318) in HEK-293 cells
and quantiﬁed co-purifying proteins. We found that both WT
and methylation-deﬁcient eEF1A efﬁciently enriched components
of the eEF1 complex (EEF1B2, EEF1G, and EEF1D) as well as
aminoacyl-tRNA synthetases (VARS and CARS) (Supplementary
Fig. 14a, b and Supplementary Data 5–6) and, importantly, that
interactants for both bait proteins were enriched with a
comparable efﬁciency (Supplementary Fig. 14c, d). We conclude
that lysine methylation of eEF1A is not a strong determinant of
its interactome.
In summary, we observed codon-speciﬁc changes in translation
rate when comparing METTL13 KO cells to the corresponding
WT and conclude that these alterations are likely due to the lack
of methylation at the N terminus and Lys55 in eEF1A.
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Discussion
eEF1A performs the important function of delivering aminoacyl-
tRNAs to the ribosome during mRNA translation and is known to
be extensively post-translationally modiﬁed. In particular, several
lysine residues as well as the N terminus are subjected to
methylation, and until very recently the responsible enzymes were
largely unknown39,40. Here, we report the identiﬁcation of human
METTL13 as a dual MTase that targets both the N terminus and
Lys55 of eEF1A through two distinct MTase domains, ﬁrmly
establishing its function using a combination of in vitro and
in vivo methods. Moreover, we demonstrate that loss ofMETTL13
gene function results in altered translation rates of distinct codons.
The function of eEF1A in mRNA translation is universally
conserved and likely highly optimized due to strong selective
pressure. Interestingly, the translation apparatus is subject to
extensive methylation41 and these modiﬁcations have been sug-
gested to ﬁne-tune and optimize interactions within the ribo-
some1. Through analysis of ribosome footprints, we determined
the occupancy of mRNA codons in the ribosomal A-site of
METTL13 KO cells, relative to their WT counterpart. The relative
occupancy of speciﬁc codons between conditions can be used to
infer changes in codon-speciﬁc global translation rates42–44.
Interestingly, we found that codons for lysine and histidine were
translated more rapidly in the WT cells, whereas translation of
alanine and tryptophan codons was faster in the KO cells.
Similarly, other PTMs of eEF1A have also been shown to affect
codon-speciﬁc translation rates15. Furthermore, modiﬁcations of
wobble uridines or cytosines in the anti-codon loop of tRNAs
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have previously been reported to alter the translation rate of
speciﬁc codons42,43,45. These ﬁndings suggest that modiﬁcations
of the different components within the ternary
eEF1A–aminoacyl-tRNA–GTP complex collectively ﬁne-tune
translation rates in the cell. Moreover, modiﬁcations of rRNA
are frequent in the active center of the ribosome46. It is tempting
to speculate that these modiﬁcations exert a similar function at
the ribosome and that all three players in A-site codon recogni-
tion (eEF1A, tRNA, and rRNA) are chemically modiﬁed to
optimize, and possibly regulate, translation. Future studies will
likely elaborate on this topic and dissect the precise molecular
mechanisms ensuring optimal translation.
Recent advances in high-resolution mass spectrometry have
enabled large-scale identiﬁcation of a variety of different PTMs47
but the enzymes responsible for introducing most modiﬁcations
remain elusive. Here, we outlined and demonstrated the use of
two types of MS-based proteomics screens linking distinct PTMs
to the respective responsible enzymes. First, we identiﬁed the
responsible enzyme for a known PTM (trimethylation of the
eEF1A N terminus) through an interaction screen using MS as
readout. Second, we identiﬁed an additional cellular
METTL13 substrate site on eEF1A using a combination of gene-
targeted cells and comprehensive proteome analysis. Notably, the
latter approach for enzyme-substrate identiﬁcation in gene-
targeted cells does not rely on PTM-speciﬁc afﬁnity enrichment
of proteolytic peptides prior to MS analysis, but rather on the
brute force of modern high-resolution MS instruments. Thus, the
approach is less labor intensive compared to enrichment-based
PTM analysis and, moreover, it is generic and likely also
applicable to PTMs beyond lysine methylation. To the best of our
knowledge, the list of 123 lysine methylation sites reported in this
study represents the most comprehensive resource of the mod-
iﬁcation generated without an afﬁnity enrichment step before MS
analysis. For comparison, the most extensive resource on basal
lysine methylation in a human cell line, generated using afﬁnity
enrichment of peptides, comprise 540 sites in HeLa cells48 and a
recent study exclusively analyzing monomethylation identiﬁed
1032 sites in KYSE-150 cells overexpressing the broad speciﬁcity
KMT SMYD249.
The most commonly studied model organisms, including D.
melanogaster (insect), C. elegans (nematode), and A. thaliana
(plant), have one-to-one orthologs of METTL1315 suggesting that
eEF1A N-terminal methylation is widespread in complex multi-
cellular organisms. Notably, the unicellular eukaryote S. cerevisiae
(budding yeast) lacks a sequence homolog of METTL13 but
encodes a functional homolog of MT13-C denoted Efm7 (sys-
tematic name YLR285W), which methylates the N terminus of S.
cerevisiae eEF1A14. Similarly to the MT13-C, Efm7 belong to the
7BS MTase superfamily, but the enzymes are otherwise only
distantly related; Efm7 belongs to the so-called MTase Family 16,
which encompasses KMTs, whereas MT13-C shows sequence
similarity to spermidine and spermine synthases (Supplementary
Fig. 2). Thus, MTases targeting the N terminus of eEF1A seem to
have independently arisen twice in evolution, suggesting that this
PTM confers a strong selective advantage.
Upon iMet cleavage, eEF1A carries a N-terminal glycine resi-
due, and NatA, the major N-terminal acetyltransferase, has been
reported to target N-terminal glycine residues50. However, we
observed no evidence of eEF1A N-terminal acetylation in
METTL13 KO cells (Supplementary Table 2). Intriguingly, a
detailed analysis of NatA substrates revealed that speciﬁc resi-
dues, including lysine and proline, are underrepresented in
position 2 (after iMet excision) in acetylated proteins51. Inter-
estingly, eEF1A has a lysine in this position and, moreover,
substrates for the NTMT enzyme exclusively have a proline.
Thus, all hitherto identiﬁed N-terminal methylation substrates
conceivably evade co-translational acetylation by harboring these
speciﬁc amino acids in position 2.
MT13-N belongs to a family of recently established KMTs,
including eEF1A-KMT4 (formerly ECE2), eEF1A-KMT2 (for-
merly METTL10), and CS-KMT (formerly METTL12). eEF1A-
KMT2 was the ﬁrst member of the family to be characterized and
targets Lys318 in eEF1A18. Very recently, CS-KMT and eEF1A-
KMT4 were reported to target Lys395 in citrate synthase52,53 and
Lys36 in eEF1A15, respectively. Here, we provide evidence that
Lys55 in eEF1A is the main substrate for MT13-N, which
represents the last characterized member of this group of KMTs.
Moreover, we show that MT13-C trimethylates the N terminus of
eEF1A. In line with the established and descriptive nomenclature
for this type of enzymes, we suggest that METTL13 be renamed
eEF1A lysine and N-terminal methyltransferase (eEF1A-KNMT;
gene name EEF1AKNMT).
Methods
Gene cloning and mutagenesis. Plasmid constructs used in this work, and the
cloning strategy used to generate them, are described in detail in Supplementary
Data 7. In brief, relevant open reading frames were ampliﬁed by PCR and cloned
into the indicated vectors using either restriction enzyme-based or ligation-
independent cloning methods. The identity and integrity of all cloned constructs
was sequence-veriﬁed.
Generation and culture of cell lines. HAP-1 METTL13 KO cells were generated
as a custom project by Horizon Genomics (formerly, Haplogen). The METTL13
gene was disrupted using CRISPR-Cas9, with guide RNA designed to target the
ﬁrst exon upstream of motifs required for enzymatic activity. Individual clones
were selected by limiting dilution and screened by sequencing. The METTL13-
deﬁcient cell line used in this study contains a 20 base pair deletion in the targeted
region and is now commercially available (Horizon Genomics,
HZGHC000537c001). Cells were cultured and complemented with a FLAG-tagged
METTL13 construct52. Cell lines for inducible expression of 3xFLAG-tagged
eEF1A1 or eEF1A2 were generated using the Flp-InTM T-RExTM-293 system
(Thermo Fischer Scientiﬁc)33. To assess potential regulation of METTL13-
mediated methylation in vivo, HeLa cells (ATCC and CCL-2) were incubated with
media containing 4NQO (2.5 μM, 2 h), cycloheximide (50 µg/ml, 1 h) anisomycin
(1 µg/ml, 1 h), or AdOx (10 μM, 48 h). All cell lines were tested for mycoplasma
infection.
Western blot. Western blots were conducted using standard procedures54 and the
following primary antibodies were used: beta-actin (Abcam; ab8227) 1:5000 dilu-
tion, eEF1A (Merck; 05–235) 1:2000 dilution, and METTL13 (Abcam; ab186008)
1:1000 dilution.
SILAC labeling and cell extract preparation. HAP-1 WT and METTL13 KO cells
were subjected to stable isotope labeling of amino acids in cell culture (SILAC) for
quantitative MS analysis of peptides and proteins. To ensure sufﬁcient statistical
power in subsequent informatics analyses, the experiments were performed in
biological triplicates. Cells were cultured in IMDM for SILAC (Thermo Fisher
Scientiﬁc) supplemented with 10% dialyzed fetal bovine serum (Thermo Fisher
Scientiﬁc), 100 U/ml penicillin and 100 U/ml streptomycin. Media for WT cells
was supplemented with the natural variants of Arg and Lys (light label; (K0R0)),
whereas media for the METTL13 KO cells was supplemented with Lys and Arg
bearing heavy isotopes of carbon and nitrogen (L-[13C6, 15N4]Arg (+10) and L-
[13C6, 15N2]Lys (+8)) (K8R10) (Cambridge Isotope Laboratories Inc., CNLM-291-
H-PK). To ensure complete incorporation of labeled amino acids in proteins, cells
were metabolically labeled for 3 weeks. Cells were cultured to ~70% conﬂuency,
washed twice with ice-cold PBS, and lysed by adding denaturing lysis buffer (6M
guanidine hydrochloride, 5 mM tris(2-carboxyethyl)phosphine, 10 mM chlor-
oacetamide, 100 mM Tris (pH 8.5)) heated to 99 °C. Cell material was harvested by
scraping, boiled for 10 min, and brieﬂy sonicated. The protein concentration was
approximated using the Bradford assay (Bio-Rad) and proteins from WT and KO
cells were mixed at a one-to-one ratio before processing for MS analysis as outlined
below.
Protein extracts for peptide pull-downs, and ion exchange-based enrichment of
eEF1A, were prepared from relevant HAP-1, or HAP-1-derived cell line, cultured
to roughly 80% conﬂuency. Cells were washed twice with ice-cold PBS and
harvested by scraping. For pull-down experiments, collected material was
resuspended in 50 mM Tris pH 8.0, 150 mM NaCl, 10 mM KCl, 3 mM EDTA, 0.1%
NP-40, 0.5 mM DTT, 5 mM NaF, 5 mM B-glycerolphosphate, 1 mM Na-
orthovanadate and 1× complete protease inhibitor tablet (Roche). Insoluble
material was separated by centrifugation at 16,000 × g for 20 min and the
supernatant used as source of interactants in pull-down experiments. For
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enrichment of eEF1A by ion exchange, cells were lyzed in 50 mM Tris pH 7.4,
100 mM NaCl, 1% Triton X-100, 10% glycerol, 1 mM DTT with 1 mM
phenylmethanesulfonyl ﬂuoride (Sigma) and 1× protease inhibitor cocktail (Sigma-
Aldrich, P8340). The supernatant after centrifugation at 16,000 × g for 20 min was
thereafter processed by ion exchange as decribed below.
Peptide pull-downs. Pull-down experiments were performed in triplicates and all
steps were performed at 4 °C with precooled buffers unless otherwise stated. High-
performance streptavidin sepharose beads (GE Healthcare) were equilibrated in
bead washing buffer (50 mM Tris pH 8.0, 150 mM NaCl, and 0.1% NP-40). Ali-
quots of 10 μl of beads were charged with 100 µg synthetic peptide corresponding
to unmodiﬁed and iMet-less N terminus of eEF1A, i.e., GKEKTHI-
NIVVIGHVDSG-KLC-biotin, and the N-terminally trimethylated counterpart
(New England Peptide) through incubation for 2 h at room temperature. The beads
were then extensively washed with bead washing buffer and transfered to a Corning
FiltrEX 96-well ﬁlter plate (Sigma). Aliquot of 2 mg of protein extract from HAP-1
cells was then added to the beads and the plate was incubated on a thermoshaker
(Eppendorf) at 700 r.p.m. for 2 h. Unbound proteins were separated by cen-
trifugation at 60 × g for 30 s. The beads were then sequentially washed two times
with 200 μl 50 mM NaCl, two times 200 μl 150 mM NaCl, and two times 200 μl
deionized water.
Proteins bound to the bait peptides were eluted and digested by adding 25 μl
2 M urea, 1 mM DTT and 5 ng/μl trypsin to each well. Tryptic digestion was
allowed to proceed for 30 min at room temperature wherafter the ﬂow-through was
collected. To collect residual proteins, each well was washed with two times 50 μl
2 M urea and 5 mM iodoacetamide. The relevant ﬂow-through fractions were
pooled and digestion was allowed to proceed for 18 h at room temperature.
Resulting peptides were then desalted using StageTips and analyzed by LC-MS/MS
as decribed below.
Expression and puriﬁcation of recombinant proteins. Expression and puriﬁca-
tion of recombinant hexahistidine (His6)-tagged proteins from E. coli was per-
formed using Ni-NTA-agarose (Qiagen)33. Recombinant eEF1A1 was additionally
puriﬁed by cation exchange (S spin column, Thermo Fisher Scientiﬁc)16. Protein
concentration was determined using Pierce BCA Protein Assay Kit (Thermo Fisher
Scientiﬁc) and single use aliquots were stored at −80 °C.
In vitro methyltransferase assays. MTase activity assays using MT13-N and
MT13-C were performed in 10 μl reactions containing MTase assay buffer (50 mM
Tris-HCl pH 7.4, 50 mM NaCl, 50 mM KCl, 1 mMMgCl2, 1 mM DTT) and 0.5 μCi
of [3H]AdoMet (PerkinElmer) ([AdoMet]total= 0.64 μM, speciﬁc activity=
78.2 Ci/mmol). Aliquot of 20 µg of protein extract or 1 µg of recombinant eEF1A1
was incubated with 1 µg of recombinant MT13-N or MT13-C. When indicated, the
reactions contained additionally 1 mM GTP or GDP. Reaction mixtures were
incubated at 30 °C for 1 h and analyzed by SDS-PAGE and ﬂuorography15,16.
Uncropped images of membranes are shown in Supplementary Fig. 15 and all
methyltransferase experiments were independently replicated at least two times.
For quantitative MTase assays, [3H]-AdoMet was diluted with non-radioactive
AdoMet (New England Biolabs) ([AdoMet]total= 32.6 μM)55. Aliquot of 6 µg of
recombinant eEF1A1 was incubated with 1 µg of recombinant MT13-C, either wild
type or mutant, at 35 °C for 1 h. Reactions were quenched by adding 10%
trichloroacetic acid (TCA), and TCA-insoluble material was subjected to liquid
scintillation counting.
For MTase assays with MS readout, [3H]AdoMet was replaced with 1 mM non-
radioactive AdoMet (New England Biolabs). In all cases, 3 μM of eEF1A substrate
was used and the concentration of MTase was varied. Samples were digested with
proteases and processed for MS analysis as described below.
Enrichment of eEF1A proteins from cells and tissues. Lysates from cultured cells
were prepared as described above and all following steps were performed at 4 °C.
eEF1A present in extracts was partially puriﬁed by cation exchange chromato-
graphy by loading lysates onto Pierce Strong Cation Exchange (S) Spin Columns
(Thermo Fisher Scientiﬁc). The ﬂow-through was discarded and the bound
material, containing eEF1A, was eluted with 50 mM Tris-HCl pH 7.4, 300 mM
NaCl and processed for MS analysis as described below. Lysates used as source of
eEF1A from rat (adult female Long Evans) organs were prepared using a tissue
grinder15,16 and eEF1A was enriched by cation exchange as described above.
Immunoprecipitation of eEF1A proteins from cells. For analysis of the methy-
lation status of eEF1A1 and eEF1A2, the above-described stable cell lines for
inducible overexpression of 3×-FLAG-tagged eEF1A proteins were used. Protein
expression was induced during 48 h with 1 µg/ml of doxycycline. Cells were then
lysed in a buffer containing 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, and 0.5%
NP-40 supplemented with a protease inhibitor cocktail (Roche). The supernatant
after ultra-centrifugation was incubated by head-over-tail rotation for 2 h at 4 °C
with anti-FLAG M2 agarose beads (Sigma). The beads were collected by cen-
trifugation using Corning FiltrEX ﬁlter plates (Sigma) and washed twice with 200 μl
50 mM Tris-HCl (pH 7.5) and 100 mM NaCl. A ﬁnal washing step was performed
with deionized water and the samples were frozen until processed for MS analysis
as described below.
Generation and methylation of peptide arrays. Peptide arrays were generated
using the SPOT method27,56. The methylation reactions were conducted by
incubating the array with PBS buffer supplemented with 0.76 μM [3H]-AdoMet
(PerkinElmer) and 250 nM MT13-C at room temperature for 1 h. For the muta-
tional scanning SPOT array, a 15-mer peptide corresponding to eEF1A-Gly2-Val16
was used as template and the ﬁrst nine residues were mutated to all proteinogenic
amino acids except tryptophan and cysteine.
The quantitative analysis of array methylation data was performed using
ImageJ57. Sequence logos were generated using WebLogo58 using a sequence
alignment as input in which the frequency of each amino acid at each position
corresponds to the relative methylation of the corresponding peptide mutant
Based on the consensus recognition sequence for MT13-C identiﬁed through
the mutation scanning array, we searched a human proteome for additional
candidate substrates. The number of candidate sequences was reduced to 49
(Supplementary Data 2), by removing redundant sequences, as well as some
sequences that complied particularly poorly with the optimal consensus sequence.
A second array containing the corresponding 49 peptides was generated and
methylated with MT13-C as described above.
Puriﬁcation of proteins from insect cells. Production was done in Sf9 insect cells
grown in HyQ® SFX medium (Fisher Scientiﬁc) infected with recombinant viral
stock of METTL13. The His6-tagged MT13-C (residues C470–V699) was isolated
using cobalt-charged TALON resin (Clontech), followed by size exclusion chro-
matography Superdex200 (GE Healthcare Life Sciences) column, pre-equilibrated
with 20 mM HEPES (pH 7.4), 150 mM NaCl, and 2 mM TCEP. The collected
protein fractions belonging to a single peak were concentrated up to 10 mg/ml and
added AdoHcy at a 1:10 molar ratio.
Protein crystallization. Diffraction-quality crystals for MT13-C (residues
C470–V699) were grown in sitting-drop vapor diffusion plates by mixing 2 μl of
MT13-C with 1 μl of 20% (w/v) polyethylene glycol 3350, 200 mM ammonium
chloride. A 30% (v/v) glycerol-supplemented reservoir solution was used as cryo-
protectant and cryo-cooled in liquid nitrogen. X-ray diffraction data were collected
at beamline 19-ID at the Advanced Photon Source, Argonne National Laboratory.
Diffraction data were processed using XDS59 and merged by Aimless60. The MT13-
C structure was determined by molecular replacement using SpdS structure (PDB
code 3GJY, 26% sequence identity to MT13-C) as a search model in PHASER61.
Structure reﬁnement and model building was carried out by REFMAC62 and
COOT63. Figures were generated using Pymol (https://www.pymol.org).
For peptide docking, the Schrodinger software suite (Schrödinger, LLC, New
York, NY, 2017) was used to model the eEFA1 hexapeptide (GKEKTH) onto
MT13-C structure (PDB code 5WCJ). The GKEKTH hexapeptide was generated
with COOT and energy minimized with Ligprep in the Schrodinger suite. Glide
grid was used to generate a grid in the hypothetical peptide binding site near motif
Post II in MT13-C, and peptide was docked with Glide docking64.
Preparation of samples for LC-MS analysis. For analysis of peptides and proteins
from SILAC-labeled cells, lysates were digested using LysC and trypsin whereafter
the resulting peptides mixture was desalted using Sep-Pak columns (Waters).
Aliquots of 2 mg of desalted peptides were separated into 46 fractions using
reversed-phase chromatography with alkaline running buffers and a Ultimate 3000
high-pressure liquid chromatography (HPLC) system (Dionex) as outlined pre-
viously30. Each fraction was acidiﬁed by adding formic acid to a ﬁnal concentration
of 0.1% and subsequently concentrated by vacuum centrifugation. The con-
centration of peptides was spectrophotometrically determined at 280 nm using a
NanoDrop instrument (Thermo Scientiﬁc). Peptides were then diluted in 5%
acetonitrile and 0.1% triﬂuoroacetic acid, whereafter 1 µg of peptide was loaded for
LC-MS/MS analysis.
For speciﬁc analysis of the methylation status of Lys55 and the N terminus of
eEF1A samples were diluted in 2M guanidine hydrochloride, 5 mM tris(2-
carboxyethyl)phosphine, 10 mM chloroacetamide, 100 mM Tris pH 8.5 and
digested with with endoproteinase Glu-C (Roche) or Chymotrypsin (Roche),
respectively. The resulting peptides were desalted, stored on and eluted from C18
StageTips65.
Mass spectrometry. Peptides from fractionated proteome samples and eluates
from StageTips were reconstituted in 0.1% triﬂuoroacetic acid and 5% acetonitrile.
All samples were analyzed using an EASY-nLC 1200 system connected to a Q-
Exactive HF mass spectrometer (Thermo Fisher Scientiﬁc) with the exception of
eEF1A enriched from rat tissues, which was analyzed on a standard Q-Exactive
instrument16. Peptides were separated on a 15 cm-long column, 75 μm inner
diameter, packed in-house with 1.9 μm C18 beads (Reprosil-Pur AQ, Dr. Maisch).
Samples were analyzed with different chromatography gradients and MS methods
tailored for the sample type.
For analysis of samples from pull-down experiments, peptides were separated
using a 60 min LC gradient and the MS was operated in a data-dependent
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acquisition mode using a top-10 method. The resolution for full scans was set to
120,000 and peptides dissociated using HCD were analyzed at a resolution of
60,000. For analysis of proteome samples, shorter gradients and faster scanning MS
methods were used. Samples were separated using 30 min gradients, the MS was
operated with a top-20-based method with resolution for full scans of 60,000 and
fragment scans at 30,000.
For speciﬁc analysis of the methylation status of Lys55 and the N terminus of
eEF1A, a combination of both targeted and data-dependent MS methods were used
and samples were typically separated on 60-min gradients. In case of targeted
analysis, masses corresponding to charge states 3, 4, and 5 of the different
methylated forms of a chymotryptic iMet-less peptide corresponding to the N
terminus (Gly2-Tyr29) of eEF1A were selected for fragmentation throughout the
gradient.
Raw MS data analysis. For publication, all raw ﬁles were analyzed with Max-
Quant (version 1.6.0.9i) and searched against a database composed of the canonical
isoforms of human proteins as downloaded from Uniprot in April 2017 (Uniprot
Complete proteome: UP_2017_04/Human/UP000005640_9606.fasta) using the
default setting with few exceptions. For analysis of SILAC-labeled samples, the
multiplicity was set to two allowing detection of light (K0R0) and heavy (K8R10)-
labeled peptides. Moreover, methylation of lysine (mono, di, and tri) and arginine
(mono and di) as well as cyclization of N-terminal glutamine to pyro-glutamate
were included as variable modiﬁcations. The match between run function20 was
activated allowing matching of features between adjacent fractions within a
replicate and corresponding fractions between replicates. Label-free quantiﬁcation
of proteins from pull-down experiment was performed using the MaxLFQ algo-
rithm20 embedded in MaxQuant21 with predeﬁned settings.
Samples corresponding to puriﬁed and in vitro methylated eEF1A were
searched against a database containing eEF1A and METTL13 only using the
default setting with few exceptions. The maximum number of variable
modiﬁcations in a peptide was restricted to 2 and the following modiﬁcations were
considered: methylation of lysine (mono, di, and tri) and arginine (mono and di) as
well as the N terminus (mono, di, and tri).
Ion chromatograms for peptides covering Lys55 and the N terminus of eEF1A
were extracted using Xcalibur Qual Browser (Thermo). Selective ion settings for
Met49-Glu68 (z= 5) in Fig. 6b, d were 472.06 (Me0), 474.86 (Me1), 477.66 (Me2),
and 480.46 (Me3), 10 p.p.m, and in Figure 6f (z= 4) 589.82 (Me0), 593.32 (Me1),
596.83 (Me2), and 600.33 (Me3), 10 p.p.m. Selective ions setting for eEF1A-Gly2-
Tyr29 (z= 5) were 601.73 (Me0), 604.53 (Me1), 607.34 (Me2), and 610.14 (Me3),
20 p.p.m. The site occupancy of the different methylated forms of the N terminus
from in vitro methylated eEF1A was approximated as the relative signal intensity
for each methylated species.
Statistics. All statistical analysis was performed using Perseus (version 1.6.0.7). For
peptide pull-downs, LFQ intensity for proteins was required in all replicates.
Volcano plots representing the log2-transformed difference of mean intensity for
each protein and the corresponding p value from a two-sided t-test were generated
using the signiﬁcance cutoffs for s0 of 0.01 and FDR at 0.01.
For comparative analysis of lysine methylation in METTL13 KO and WT cells,
the intensities for sites were extracted in both the heavy (KO) and light (WT)
isotope channel. To enable statistical analysis of data, the intensity values for sites
not identiﬁed in all samples were imputed from the lower tail of the abundance
distribution. The data were then visualized in a volcano plot using the parameters
described above.
For analysis of proteome data, common contaminants and proteins hitting the
reverse decoy database were ﬁltered out prior to analysis. Proteins of different
abundance in WT and METTL13 KO cells were categorized using the signiﬁcance
B test (p < 0.05) with p values corrected for multiple hypothesis testing using the
Benjamini–Hochberg method.
Ribosome proﬁling. Libraries of ribosome-protected mRNA footprints from
HAP-1 cells were generated in biological triplicates for HAP-1 METTL13 KO and
in duplicates for the WT cells (Supplementary Table 3)15,16. Brieﬂy, 100 µg/ml
cycloheximide (CHX) was added to cultures for 1 min, cells were washed with cold
PBS containing 100 µg/ml CHX and in a lysis buffer (10 mM Tris pH 7.5, 100 mM
NaCl, 10 mM MgCl2, 1% Triton X-100, 0.5 mM DTT, and 100 µg/ml CHX).
Lysates were treated with 250 U RNase I (Ambion) for 10 min at 22 °C and the
digestion was stopped with 100 U SUPERase-In (Ambion). Ribosome species were
separated on a 10–50% (w/v) sucrose gradient in 50 mM Tris pH 7.5, 50 mM
NH4Cl, 12 mM MgCl2, 0.5 mM DTT, 100 µg/ml CHX for 3 h at 154,000 × g and
4 °C in a TH-641 rotor (Thermo Scientiﬁc). OD250 was recorded and monosomal
fractions collected with a density gradient fractionator (Brandel). RNA was isolated
from monosomes, separated on 15% polyacrylamide gels (8 M urea, 1× TBE) and
28–32 nt ribosome footprints were extracted. Sequencing libraries were generated
essentially as described by Ingolia and colleagues66, except for ligation to a pre-
adenylated 3′-adapter with four randomized nucleotides (5′-rAppNNNNCTG-
TAGGCACCATCAAT/3ddC/-3′) to minimize ligation biases67.
To determine A-site codon occupancy, we used a published strategy and
excluded the ﬁrst 15 nucleotides of each ORF from analysis to remove biases
inﬂuencing codon frequency at the initiation site43: 29–31 nt long reads starting in
the 0-frame were used and the A-site deﬁned as positions 15–17 from the start of
the read. Occupancy was normalized to the adjacent codons in the +1, +2, and +3
positions. Ribosome occupancy at the +1 position (18–20 nt from the start of the
read) was similarly normalized by occupancy of the +2, +3, and +4 positions.
Code availability. Scripts used to generate codon occupancy plots using Perl and R
are available from the corresponding authors on request.
Data availability. Ribosome proﬁling data have been deposited at the Gene
Expression Omnibus (accession number: GSE104033). The mass spectrometry
proteomics data have been deposited to the ProteomeXchange Consortium via the
PRIDE68 partner repository with the data set identiﬁers PXD008115 (peptide pull-
downs), PXD008131 (SILAC-based proteome), PXD009895 (eEF1A WT and 5KR
interactome), and PXD009914 (HeLa cell stress screen). Atomic coordinates and
structure factors of MT13-C in complex with AdoHcy was deposited in the Protein
Data Bank under accession code PDB 5WCJ. All other data are available on
request.
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